A review on biomarkers for prediction of treatment outcome in gastric cancer

摘要: Currently, therapeutic management of gastric cancer is mainly based on clinical data and histological features. Although several new treatment options have recently been introduced, inter-individual variability response drug resistance are still a challenge. Many promising markers identified to predict prognosis likelihood therapy, in order tailor regimens the basis patients' individual However, despite recent developments gene sequencing molecular diagnostics, many biomarkers controversial role. Published often contradictory at moment, no marker, other than Human epidermal growth factor receptor-2 (HER2) status for trastuzumab-based treatment, has entered mainstream practice. The primary obstacle identification reliable lies technical difficulties quantitatively assessing alterations; genome-wide analyses also misleading due complexity biological processes. Nevertheless, being evaluated trials identify criteria stratifying patients establish customized approaches. In this review, we provide an update prognostic predictive markers, with focus signalling molecules, DNA repair systems, fluoropyrimidine metabolism apoptotic pathways.